ArticleInvestigational new drugs2013

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.

Don G Morris et al.PubMed ↗Publisher ↗

No numbers read from the abstract.